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Novel lines of Pax6-/- embryonic stem cells
exhibit reduced neurogenic capacity without loss
of viability
Jane C Quinn1,2*, Michael Molinek1, Tomasz J Nowakowski1, John O Mason1, David J Price1
Abstract
Background: Embryonic stem (ES) cells can differentiate into all cell types and have been used extensively to
study factors affecting neuronal differentiation. ES cells containing mutations in known genes have the potential to
provide useful in vitro models for the study of gene function during neuronal differentiation. Recently, mouse ES
cell lines lacking the neurogenic transcription factor Pax6 were reported; neurons derived from these Pax6-/- ES
cells died rapidly after neuronal differentiation in vitro.
Results: Here we report the derivation of new lines of Pax6-/- ES cells and the assessment of their ability to survive
and differentiate both in vitro and in vivo. Neurons derived from our new Pax6-/- lines were viable and continued
to elaborate processes in culture under conditions that resulted in the death of neurons derived from previously
reported Pax6-/- ES cell lines. The new lines of Pax6-/-ES cells showed reduced neurogenic potential, mimicking the
effects of loss of Pax6 in vivo. We used our new lines to generate Pax6-/- ↔ Pax6+/+ chimeras in which the mutant
cells survived and displayed the same phenotypes as Pax6-/- cells in Pax6-/- ↔ Pax6+/+ chimeras made by embryo
aggregation.
Conclusions: We suggest that loss of Pax6 from ES cells reduces their neurogenic capacity but does not
necessarily result in the death of derived neurons. We offer these new lines as additional tools for those interested
in the generation of chimeras and the analysis of in vitro ES cell models of Pax6 function during neuronal
differentiation, embryonic and postnatal development.
Background
Pax6 is a highly-conserved transcription factor whose
main sites of expression are in the developing eye and
central nervous system [1-5]. Homozygous loss-of-func-
tion mutations of Pax6 cause failure of eye morphogen-
esis and severe abnormalities of brain development [6,7].
Pax6 plays an important role promoting neurogenesis; in
vivo, loss of Pax6 results in neural progenitors having
reduced neurogenic potential [8,9] whereas its over-
expression in vitro pushes cells towards a neuronal fate
[8,10,11]. The mechanisms by which Pax6 directly pro-
motes neurogenesis are not yet known.
Pluripotent embryonic stem (ES) cell lines have pro-
vided a means to exploit gene targeting for the analysis
of gene function in vivo. In addition, since ES cell lines
can be differentiated into a variety of cell types in cul-
ture they provide an opportunity to study gene function
by comparing the phenotypes of ES-derived cells in
vitro. ES cells have been used systematically as a model
system for examining factors controlling differentiation
pathways in vitro. In particular, differentiation protocols
have been reported which recapitulate differentiation of
various neuronal cell types, or their precursors, in vitro
[12-17].
Recently, ES cell lines derived from mouse embryos
lacking Pax6 (Pax6-/-) were studied in culture [11]. Neu-
rons derived from these Pax6-/- ES cells died rapidly
after induction of neuronal differentiation, with almost
none surviving beyond about a week after plating. This
is surprising as Pax6-/-neurons can survive into postna-
tal life following transplantation into wild-type embryos
[18] and following early embryonic neural tissue-specific
conditional deletion of Pax6 [19] suggesting that loss of
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Pax6 alone is not necessarily sufficient to abolish neuro-
nal viability.
We derived new lines of Pax6-/- ES cells and assessed
their ability to survive and differentiate both in vitro
and in vivo. These new lines (which are labelled with a
developmentally neutral nuclear transgenic marker)
were used to generate Pax6-/- ↔ Pax6+/+ chimeras in
which the mutant cells survived and displayed the same
phenotype as Pax6-/- cells in Pax6-/- ↔ Pax6+/+ chi-
meras made by embryo aggregation [9,20-22]. In vitro,
we found that the new lines of Pax6-/- ES cells showed
reduced neurogenic potential, mimicking the effects of
loss of Pax6 in vivo. Contrary to previous reports that
ES-derived cells lacking Pax6 show reduced process
development as little as 4 days after plating and die 2-4
days later [11], cells derived from these new Pax6-/-
lines were viable and continued to elaborate their pro-
cesses after comparable culture times under comparable
conditions. We offer these lines as a validated tool for
investigation of gene function during neuronal differen-
tiation in vitro and the generation of chimeric animals
for in vivo analysis of development of the central ner-
vous system.
Methods
Animals
Animals in this study were bred in-house following
Home Office (UK) regulations and were approved by
the University of Edinburgh Ethical Review Panel.
Derivation of Pax6-/- ES cells
ES cells that were either wild type (Pax6+/+) or Pax6SeyEd/
SeyEd (designated here as Pax6-/-; [23] were derived using
the following protocol. Female mice [129Sv(Ola); Pax6
+/-] were superovulated and mated with males [129Sv
(Ola)] that were Pax6+/- and homozygous for a reiterated
b-globin repeat transgene (Tg/Tg; [24], which acts as a
developmentally neutral marker detectable by DNA-
DNA in situ hybridization [9,20,22,25]. Delayed implan-
tation (diapause) was induced at 2.5 days post coitum
(dpc) by intraperitoneal injection of Tamoxifen (Sigma,
UK; 10 μg/animal) and subcutaneous injection of Depo-
Provera (Sigma, UK; 1-3 mg/animal). At 7.5 dpc delayed
blastocysts were flushed from the uterus, transferred to a
gelatinised well containing N2B27 medium (Stem Cell
Sciences, UK) with 10 ng/ml Leukaemia Inhibitory Factor
(LIF) and cultured at 37°C in 5% CO2. After approxi-
mately 5 days in culture, the inner cell mass was
detached from the bottom of each well using a fine pulled
Pasteur mouth pipette before being disaggregated in tryp-
sin (0.025% for 2-3 minutes at 37°C) and disrupted to
give individual clusters of between 1-5 cells. Cell clusters
were then transferred to a fresh gelatinised well contain-
ing N2B27 media containing LIF (1000 U/ml) with the
addition of BMP4 (10 ng/ml). Primary colonies of ES
cells were visible after approximately 5 days in culture.
ES cell lines were passaged at least twice in feeder-free
conditions in BHK-21 Glasgow MEM (GMEM; Sigma,
UK) with 15% fetal bovine serum (FBS) and LIF (1000 U/
ml). Cell lines were genotyped as described previously
[9]. All cell lines were karyotyped to confirm normal
chromosome complement.
Chimera production
Chimeric embryos were produced by blastocyst injection
and processed histologically, by in situ hybridization and
immunohistochemistry, to detect cells carrying the Tg
marker and to analyse their expression of transcription
factors, as described before [9].
Neural differentiation
The neural differentiation protocol followed a previous
description [14]. Briefly, ES cells maintained in feeder-
free conditions were plated in non-adherent dishes in
GMEM +15% FBS in the absence of LIF (designated
Day 0, or day of LIF withdrawal). After 4 days, all-trans
retinoic acid (5 μM, Sigma, UK) was added. The devel-
oping embryoid bodies (EBs) were allowed to develop
for a further 2 or 4 days (to Days 6 or 8) before disso-
ciation using Tryple Express™ (Invitrogen, UK). EBs
taken on Day 6 and some of those taken on Day 8 were
exposed to 40 μg/ml bromodeoxyuridine (BrdU) for 30
minutes before being dissociated and plated for two
hours in 8-well glass chamber slides, fixed with parafor-
maldehyde and processed for immunohistochemistry.
Other cells dissociated on Day 8 were plated at 2.0 ×
105 cells/cm2and cultured in serum-free GMEM/F12:
Neurobasal medium (1:1) supplemented with N2 and
B27 (Invitrogen, UK) for 6 or 8 days (to Days 14 or 16
after LIF withdrawal) before fixation and processing.
Primary cortical progenitor cell cultures
The cortices of E11.5 embryos generated from timed
matings of Pax6+/- animals were isolated. Each cortex
was kept separate, its cells were dissociated into separate
wells and were allowed to grow for 7 days in DMEM:
F12 1:1 culture media supplemented with 100 μg/ml
transferrin, 25 μg/ml insulin, 20 nm progesterone, 30
nm sodium selenite, 60 μg/ml putrescine, 20 ng/ml EGF
and bFGF (all Sigma, U.K). The genotypes of individual
embryos were discovered by PCR analysis as described
previously [20]. Primary neurospheres were dissociated
on Day 7 and stained with propidium iodide for analysis
using flow cytometry.
Immunohistochemistry and flow cytometry analysis
Antibodies used in this study were against b-III-tubulin
(Sigma, UK), microtubule associated protein 2 (MAP2;
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Sigma), UK, Pax6 (Developmental Studies Hybridoma
Bank, USA), glial fibrillary acid protein (GFAP; DAKO,
UK) and BrdU (Beckton Dickinson, UK). Visualisation
was achieved using Alexafluor-488 or Alexafluor-568
(Invitrogen, UK) conjugated secondary antibodies and
cell nuclei were counterstained using TOPRO3 (Molecu-
lar Probes, USA). For counting, 3-8 areas were selected
randomly per well. Apoptotic cells were identified by
their dense chromatin condensation visible with
TOPRO3 staining. Chromatin condensation was easily
recognized, is a defining feature of apoptosis [26] and
has been shown previously to coincide with other indi-
cators of apoptosis such as terminal deoxynucleotidyl
transferase-mediated biotinylated UTP nick end labelling
(TUNEL) [27].
For flow cytometry, cells were stained with propidium
iodide to allow discrimination of single cells and analysis
of DNA content. Staining reactions were carried out in
duplicate. Cells were analyzed on a Beckman-Coulter
XL flow cytometer with Expo32 software. 8,000-20,000
cells were analyzed per sample.
In vitro transfection
Sub-confluent Pax6-/- ES cells were dissociated using
Tryple Express™ and plated in GMEM media containing
LIF and FBS. Twenty-four hours later they were co-
transfected using Fugene (Invitrogen, UK) with pCMV-
Script plasmid containing the full length Pax6 cDNA
[10] and plasmid pEGFPN1 (Clontech, USA) expressing
green fluorescent protein (GFP). Transfected cells were
selected by culture in medium containing G-418 (500
μg/μl). After 7 days in selection medium individual colo-
nies were picked and expanded by routine passage in
GMEM+FBS+LIF. Stably transfected cell lines were sub-
jected to neural induction as described above and cul-
tures fixed for immunohistochemistry at Day 14.
Results
Derivation of Pax6-/- ES cell lines and generation of
Pax6-/- ↔ Pax6+/+ chimeras
We established 9 lines of Pax6+/+ ES cells (wtMM1-9)
and three lines of Pax6-/- ES cells (SeyD1-3) containing
the Tg transgene [24]. Karyotyping of these ES cell lines
showed that each had a normal chromosome comple-
ment [28]. Pax6-/- ES cell lines displayed no abnormal-
ities of growth during routine passage; two (SeyD1 and
SeyD2) were analysed in detail.
The developmental potential of wild type line wtMM4
and Pax6-/- line SeyD1 was assessed by injection into
wild type blastocysts to create chimeras. We produced
ten Pax6-/-↔ Pax6+/+ chimeras aged between embryonic
day (E) 10.5 and postnatal day (P) 5 and ten control Pax6
+/+ ↔ Pax6+/+ chimeras aged between E10.5 and E14.5.
In controls, Tg+ cells derived from wtMM4 were
distributed throughout eye and brain tissues, which
exhibited no abnormal phenotypes. In Pax6-/-↔ Pax6+/+
chimeras, Tg+Pax6-/- cells derived from SeyD1 showed
abnormal distributions in eye and brain tissues, similar to
those reported previously for Pax6-/- cells in Pax6-/- ↔
Pax6+/+ chimeras produced by aggregation of Pax6+/+
and Pax6-/- morulae [9,20,22,25]. For example, Pax6-/-
cells derived from SeyD1 formed clusters in the subven-
tricular zone of the embryonic cortex (Figure 1A, B);
these clusters expressed inappropriate markers of ventral
telencephalic identity, such as Mash1 (Figure 1B), as pre-
dicted from previous work [9,22]. Pax6-/- cells derived
from SeyD1 failed to contribute to the lens and exhibited
extreme segregation from wild type cells in the neural
retina, which exhibited areas of characteristic abnormal
retinal folding (Figure 1C, D), again as anticipated from
previous studies [20]. Clusters of Pax6-/- cells derived
from SeyD1 were still present in the brains of postnatal
chimeras (Figure 2). These findings indicate that cells
derived from Pax6-/- ES cells can contribute in predicta-
bly abnormal ways to the eyes and brains of chimeras for
periods extending into postnatal life, long after the onset
of neurogenesis.
Comparison of proliferation, apoptosis and onset of
differentiation in wild type and Pax6-/- cells derived from
wtMM4, SeyD1 and SeyD2 at Days 6-8 in vitro
It is known that many Day 8 cells from wild-type
embryoid bodies made with the protocol used here
express markers of neural progenitors [11]. In agree-
ment with this, only a few percent of Day 8 cells from
embryoid bodies from our new wild-type wtMM4 ES
cell line expressed the marker of differentiating neurons,
b-III-tubulin (Figure 3). Most of the cells that did not
express neuronal markers were positive for the marker
of neural progenitors, Nestin (60.7% ± 3.2 s.e.m., n = 4
cultures), and the marker of cortical apical progenitors,
RC2 (51.7% ± 3.5 s.e.m., n = 4 cultures).
Embryoid bodies (EBs) from previously-derived Pax6-/-
ES cells contained normal complements of neuronal
progenitors [11]. In agreement with this, we found that
proportions of BrdU-labelled proliferating cells were no
different between wtMM4, SeyD1 and SeyD2 EBs (Fig-
ure 3). We also compared proportions of cells positive
for the progenitor markers RC2 and Nestin in EBs on
Day 8 and found no evidence of differences between the
proportions of progenitors in EBs from our new wild
type and Pax6-/- lines, in agreement with a similar com-
parison by Nikoletopoulou et al. [11] of their wild-type
and mutant lines.
Proportions of BrdU-labelled proliferating cells
declined between Day 6 and Day 8 after LIF withdrawal,
coinciding with the onset of differentiation (Figure 3).
Small proportions of b-III-tubulin-expressing cells were
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detected on Day 8 after LIF withdrawal and small pro-
portions of cells labelled with BrdU on Day 8 were also
b-III-tubulin-positive several hours later. There were no
differences in the proportions of early differentiated
neurons between cultures from wild type and Pax6-/-
lines at Day 8 (Figure 3). Overall, these data indicate
that neuronal differentiation is just beginning on Day 8
and the time of onset is not perturbed by the loss of
Pax6 expression in our ES cells.
Proportions of apoptotic cells on Day 6 and Day 8
after LIF withdrawal were low with no significant differ-
ences between the wild-type and the Pax6-/- ES cells
(Day 6: Pax6+/+ mean percentage of apoptotic cells =
5.42% ± 1.82 s.e.m., n = 5 cultures; Pax6-/- mean =
7.64% ± 3.05, n = 5; Day 8: Pax6+/+ mean = 2.44% ±
1.27, n = 5; Pax6-/- mean = 1.62% ± 0.65, n = 5).
Reduced proportions of neurons in cells of SeyD1 and
SeyD2 lines at Day 14 in vitro
Previous reports have shown that the differentiation
protocol used in this study induces a large majority of
b-III-tubulin expressing neurons from wild type ES cells
after several days in vitro [14]. Similarly, we found that
about 80% of dissociated cells from the wild type ES cell
line wtMM4 were positive for b-III-tubulin on Day 14
after LIF withdrawal) with about 50% of cells positive
for the later neuronal marker MAP2 (Figure 4A, B, G).
In contrast, Pax6-/- ES cell lines SeyD1 and SeyD2 lines
showed a significantly lower proportion of cells positive
for b-III-tubulin and MAP2 (around 20-30%) in Day 14
cultures (Figure 4C-G). These findings indicate that ES-
derived progenitors lacking Pax6 have reduced neuro-
genic potential, as do Pax6-/- primary progenitors
Figure 1 Pax6-/- cells derived from mutant ES cells integrate in Pax6-/- ↔ Pax6+/+ chimeras and show predictably abnormal
phenotypes. (A-D) In these E14.5 chimeras, mutant cells are recognized by a brown nuclear spot, which is the result of DNA-DNA in situ
hybridization for a reiterated b-globin transgene. (A,B) Sections of the cerebral cortex showing clusters of Pax6-/- cells in the subventricular zone;
these cells are positive for Mash1 (grey staining in B). (C,D) In the eye, chimeras show abnormal retinal morphologies (boxed area) exhibiting
extreme segregation between wild type and mutant cells, similar to abnormalities reported previously in aggregation chimeras [20]. The
arrowhead in D indicates an example of the boundary between an area of mutant and an area of wild type cells with abnormal retinal folding.
Scale bars: A,B,D = 50 μm; C = 100 μm.
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derived from mutant embryos and Pax6-/- cells develop-
ing in the cortex of Pax6 mutant chimeric embryos
[8,9].
To confirm that the reduced neurogenic potential of
our SeyD1 and SeyD2 ES cell lines was due to loss of
Pax6, we generated two stably transfected Pax6-/- ES
cells lines, SeyD1-TF1 and SeyD1-TF2, which expressed
full length Pax6 transcript under the control of a
constitutive promoter. Pax6 expression in these cells
was confirmed by immunohistochemistry to Pax6 pro-
tein (Figure 5A, B). SeyD1-TF1 and SeyD1-TF2 ES cell
lines generated cultures that, on Day 14, consisted
almost entirely of neurons. These neurons produced
long processes similar to those seen in wild-type cul-
tures of wtMM4 neurons (Figure 5C, D). Only very
small numbers of cells could be identified in each
Figure 2 Pax6-/- cells derived from mutant ES cells are still present in postnatal Pax6-/- ↔ Pax6+/+ chimeras. Mutant cells clustered (A) in
cortex, (B) at the corticostriatal boundary and (C) in the hippocampus at P5; arrows in A point to examples of labelled mutant cells. Scale bar:
A = 50 μm; B,C = 30 μm.
Figure 3 Pax6-/- mutant ES cells generate embryoid bodies containing normal proportions of proliferating and differentiating cells.
(A) Histograms show percentages of cells positive for either BrdU, b-III-tubulin or both two hours after plating cells from dissociated EBs that had
been exposed to a short pulse of BrdU shortly before dissociation. From left to right: percentages of all cells that were BrdU positive on Day 6
after LIF withdrawal; percentages of all cells that were BrdU positive on Day 8; percentages of all cells that were b-III-tubulin positive on Day 8;
percentages of BrdU positive cells that were b-III-tubulin positive on Day 8. All values are means of 3 or 4 independent culture runs ± standard
errors. No significant difference was observed between the wild type and Pax6-/- mutant ES cell lines within each culture paradigm. (B) Examples
of wtMM4 cells that are BrdU positive (red), b-III-tubulin positive (green), double-labeled (yellow arrow) and labeled only with TOPRO3
counterstain (blue).
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Figure 4 Pax6-/- ES cells generate abnormally low proportions of neurons. (A-F) Examples of cultures of cells derived from wtMM4, SeyD1
and SeyD2 lines on Day 14 after LIF withdrawal stained with either b-III-tubulin or MAP2 (green) and TOPRO-3 (blue). (G) Mean percentages
(± standard error of the mean; n = 3-4 independent cultures per line) of b-III-tubulin (open bars) or MAP2 (grey bars) expressing neurons are
shown for each ES cell line. Percentages of b-III-tubulin-positive and MAP2-positive neurons were significantly reduced in Pax6 mutant ES cell
lines SeyD1 and SeyD2 (with Student’s t-tests, differences for b-III-tubulin were both p < 0.0001 and for MAP2 were both p < 0.02).
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SeyD1-TF1 and SeyD1-TF2 culture which did not
express the marker of early neuronal differentiation, b-
III-tubulin (Figure 5D). Accurate quantification of the b-
III-tubulin-negative cells was not possible due to the
extensive process development, but it was clear that
proportions of neurons were much higher than the 20-
30% observed in the founder mutant SeyD1 and SeyD2
lines (Figure 4G). These results indicate that transfection
of SeyD1 and SeyD2 with a construct expressing the full
length Pax6 transcript reversed their defective neuro-
genic potential.
Continuing development of cells derived from SeyD1
and SeyD2 at Day 16
To determine cell viability after longer periods in cul-
ture, we allowed cells derived from our Pax6+/+, Pax6-/-
SeyD1 and SeyD2 lines to continue to grow in culture
to Day 16 post LIF withdrawal. At this time under com-
parable culture conditions, neurons derived from
previously reported Pax6-/- ES cell lines had all died
[11]. In contrast, neurons derived from our Pax6-/-
SeyD1 and D2 lines continued to elaborate large mesh-
works of b-III-tubulin-positive processes (Figure 6)
showing no noticeable loss of viability after 16 days in
culture.
As at Day 14, many Pax6-/- SeyD1 and D2 cells
remained negative for b-III-tubulin at Day 16 but the
extensive processes surrounding all cells in the cultures
made it impossible to count proportions of these b-III-
tubulin-negative cells accurately. We found that some
cells in wtMM4 and SeyD1 and SeyD2 lines were positive
for GFAP, a marker of cells of glial identity (Figure 6).
Primary neural progenitors lacking Pax6 do not exhibit
enhanced cell death
To test whether primary neural progenitors derived
from Pax6-/- embryos showed increased cell death in
culture, neural progenitors were isolated from wild
Figure 5 Re-expression of Pax6 induces extensive neurogenesis from Pax6-/- ES cells. (A, B) Immunocytochemistry for Pax6 (green) does
not label cells derived from the founder Pax6-/- line SeyD1 (A) whilst Pax6 expression is observed in cells generated from this line that were
stably transfected with a Pax6-expression construct (SeyD1-TF1) (B). (C) At Day 14, wild type ES cell-derived cultures contain large numbers of
b-III-tubulin-expressing neurons (green; see also Figure 4) with small proportions of GFAP-positive cells (red). (D) At Day 14, almost all SeyD1-TF1
cells (i.e. Pax6-/- cells containing a Pax6-expression construct) are b-III-tubulin-expressing neurons (contrasting with results from untransfected
Pax6-/- cells at this age, see Figure 4), with a small proportion of GFAP-positive cells.
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type and Pax6 mutant cortex at E11.5 and expanded in
vitro for 7 days. Neurospheres were dissociated and
proportions of dead cells were determined from the
size of the hypodiploid (subG1) population of cells by
flow cytometry as described previously [8]. No signifi-
cant difference was observed in the proportions of
hypodiploid cells between the wild-type and mutant
cells (mean percentages of cells in subG1 were: Pax6
+/+, 12.6% ± 2.10 s.e.m.; Pax6-/-, 7.8% ± 2.85, n = 3
cultures each). These data indicate that loss of Pax6 in
primary neural progenitors does not increase cell
death.
Discussion
In many respects, the in vitro development of our new
Pax6-/- ES cells resembles that of previously derived
Pax6-/- ES cells [11] and that of primary Pax6-/- pro-
genitors taken from mutant embryos [8]. Firstly, our
new wild-type and Pax6-/- mutant lines produced EBs
containing proliferating progenitors in large proportions
that were similar to those in EBs of wild type ES cells
and of previously derived Pax6-/- ES cells. This agrees
with a previous conclusion that the generation of early
neurogenic progenitors from ES cells is not perturbed in
the absence of Pax6 [11]. Secondly, Nikoletopoulou et
al. [11] showed that abnormally high proportions of
these progenitors expressed the ventral telencephalic
marker Mash1; similarly, we found abnormal ectopic
expression of Mash1 in Pax6-/- ES-derived cells in the
dorsal telencephalon of chimeras. Thirdly, previous stu-
dies have shown that primary Pax6-/- progenitors from
mutant cortex generate reduced proportions of neurons
in culture [8]; we found the same trend in cells differen-
tiated from our lines of Pax6-/- ES cells in vitro.
Together these data suggest that our novel Pax6-/- ES
cell lines are mimicking the in vivo and in vitro
characteristics of neuronal progenitors derived from pri-
mary tissue of the Pax6-/- embryo.
In one respect, however, our new Pax6-/- ES cell lines
developed quite differently to Pax6-/- ES cell lines
reported previously. Our Pax6-/- ES cell-derived neurons
showed no signs of early failure of process development
and the extensive cell death previously reported; on the
contrary, they were continuing to develop ever more
elaborate processes at an age when virtually all of the
previously described cells had died [11].
Since the culture protocol we used is similar to that
used to differentiate previously derived Pax6-/- ES cells,
possible explanations for this difference in viability must
centre of the nature of the ES cells themselves. One
possibility is variation in genetic background. Our ES
cells were derived from Pax6 mutant mice inbred on a
129Sv(Ola) background whereas those used by Nikoleto-
poulou et al. [11] were not (N.D. Allen, personal com-
munication). It is possible that genetic background is
critical for the manifestation of abnormally high levels
of cell death observed in the previous study. This may
not be surprising as genetic background has been shown
to play a role in determining the exact nature of the eye
and craniofacial defects associated with the Pax6-/- phe-
notype [29].
Nikoletopoulou et al. [11] did not report the pheno-
type of Pax6-/- cells derived from their mutant ES cells
in mouse chimeras. They did, however, describe the
introduction of Pax6-/- ES cell derived progenitors into
chick telencephalon: some of the neurons derived from
these cells survived in the chick telencephalon, suggest-
ing that even in these cells the absence of Pax6 does not
necessarily cause extensive cell death given an appropri-
ate supporting environment. Therefore induction of
Pax6 genotype-dependent neuronal cell death might
depend on both the genetic background of the mutant
Figure 6 Neurons from Pax6-/- ES cell lines remain viable and continue to elaborate processes after 16 Days in culture. (A) Wild-type
wtMM4 cells and (B) Pax6-/- cells from the SeyD1 and (C) SeyD2 lines labeled for b-III-tubulin (green) and GFAP (red), with TOPRO-3
counterstaining (blue). Cells derived from all three ES cell lines are viable and have continued to make elaborate processes.
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cells and the environment in which they are placed. It
seems quite conceivable that loss of Pax6 from ES cells
might cause the rapid death of all derived cells with
some genetic backgrounds in vitro but not in vivo,
whereas loss of Pax6 from ES cells with other genetic
backgrounds might generate cells that are viable both in
vitro and in vivo, as is the case in our novel Pax6
mutant cell lines.
Although Nikoletopoulou et al. [11] suggested that the
rapid death of all Pax6-/- ES cell derived neurons in cul-
ture reflects an increased incidence of cell death in the
cerebral cortex of Pax6-/- mice, other studies did not
report an increase in apoptotic cells in the Pax6-/- cor-
tex in vivo or among Pax6-/- primary cells in culture
[8,9,30]. Data included in this present study on cultured
cells from embryos support previous evidence against an
increase in cell death in the absence of Pax6. On the
contrary, Pax6-/- neurons have been shown to survive
for extended periods, even into postnatal life following
transplantation into wild type embryos [18] and follow-
ing early embryonic neural tissue-specific deletion of
Pax6 [19]. In the present study Pax6-/- ES-derived neu-
rons in chimeras also survived into postnatal life. Over-
all, most published studies point to the importance of
Pax6 in the early regulation of neurogenesis [8,9,30-33],
whereas the evidence that Pax6 has a prominent role in
cell death remains controversial.
Conclusion
In conclusion, we have successfully derived Pax6-/- ES cells
that develop in ways predicted from previous work on
Pax6-/- progenitors and neurons in vivo and in vitro. Neu-
rons derived from our new lines show enhanced viability
compared to neurons derived from previously studied
Pax6-/- ES cell lines. Our new lines offer a good model for
the study of Pax6 gene function in vivo and in vitro.
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